Arimidex approved for early breast cancer

Arimidex (anastrozole) has been licensed for the adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received two to three years of adjuvant tamoxifen.

In a phase III trial conducted in 2,579 postmenopausal women with hormone receptor positive early breast cancer who had received surgery with or without radiotherapy and no chemotherapy, switching to Arimidex after two years adjuvant treatment with tamoxifen was statistically superior in terms of disease-free survival compared with remaining on tamoxifen, after a median follow up of 24 months.

Further information: AstraZeneca UK Ltd, Horizon Place, 600 Capability Green, Luton, Beds LU1 3LU. Tel: 01582 836836.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more